Taiwanin A targets non-steroidal anti-inflammatory drug-activated gene-1 in human lung carcinoma

Harn, Horng‐Jyh; Chuang, Hong-Meng; Chang, Li-Fu; Huang, Angela Yu Hsuan; Hsieh, Shin-Ta; Lin, Shinn‐Zong; Kuo, Yueh‐Hsiung; Chiou, Tzyy‐Wen

doi:10.1016/j.fitote.2014.08.020

Cited by 9 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibition of EZH2 expression prevented its binding to the GDF15 promoter region and reduced the trimethylation modification pattern of H3K27; an increase in GDF15 expression was observed . An anticancer compound, Taiwanin A, also exhibited GDF15 induction in human lung carcinoma (Harn, et al, 2014). These findings are consistent with a tumor suppressor role for GDF15 in non-small cell lung cancer.…”

Section: -1 Lung Cancersupporting

confidence: 81%

“…Baek and Eling Page 30 (Cekanova, et al, 2009) SPCA1 and H1299 cells Anti No A549 and H460 cells Anti No (Harn, et al, 2014) H460 cells Anti No (Kadara, Schroeder, Lotan, Pisano, & Lotan, 2006) A549 cells Pro No (Zhao, et al, 2018) Colorectal cancer HT29 and SW480 cells Pro Yes (C. HCT-116 cells Anti No (Baek, Kim, Nixon, Wilson, & Eling, 2001) GDF15 knock-out/MIN mouse Anti No (Zimmers, Gutierrez, & Koniaris, 2010) Azoxymethane-induced mouse model and MIN mouse model in GDF15 Tg mice Anti No Prostate Positive and Negative Health Effects of GDF15 observed in mice.…”

Section: Author Manuscript Author Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases

Baek

Eling

2019

Pharmacology & Therapeutics

136

104

View full text Add to dashboard Cite

Growth Differentiation Factor 15 (GDF15), also known as NSAID activated gene-1 (NAG-1), is associated with a large number of biological processes and diseases, including cancer and obesity. GDF15 is synthesized as pro-GDF15, is dimerized, and is cleaved and secreted into the circulation as a mature dimer GDF15. Both the intracellular GDF15 and the circulating mature GDF15 are implicated in biological processes, such as energy homeostasis and body weight regulation. Although there have been many studies on GDF15, GFRAL, a member of the glial-derived neurotropic factor receptor α family, has only been recently identified as a receptor for mature GDF15. In this review, we focused on cancer and energy homeostasis along with obesity and body weight, and the effect of the identification of the GDF15 receptor in these investigations. In addition, the therapeutic potential of GDF15 as a pharmacological agent in obesity and other metabolic diseases was discussed.

show abstract

Section: -1 Lung Cancersupporting

confidence: 81%

Section: Author Manuscript Author Manuscriptmentioning

confidence: 99%

Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases

Baek

Eling

2019

Pharmacology & Therapeutics

136

104

View full text Add to dashboard Cite

show abstract

“…Treatment of A549 cells with isochaihu-lactone induced NAG-1 by activating EGR-1 on the NAG-1 promoter [210]. Human lung carcinoma cell lines A549 and NCI-H460 treated with Taiwanin A showed decreased cell viability with increased NAG-1 protein, and JNK inhibitors decreased NAG-1 mRNA levels [211]. Treatment of AGS, a human gastric adenocarcinoma cell line, with hispidulin, a naturally occurring flavone, also induced cell cycle arrest, apoptosis and NAG-1 expression, while COX-2 expression was downregulated by the activation of ERK1/2 [212].…”

Section: Roles Of Nag-1 Activated By Phytochemicals In the Prevention Of Inflammation-mediated Tumorigenesismentioning

confidence: 96%

Natural Products in the Prevention of Metabolic Diseases: Lessons Learned from the 20th KAST Frontier Scientists Workshop

et al. 2021

View full text Add to dashboard Cite

The incidence of metabolic and chronic diseases including cancer, obesity, inflammation-related diseases sharply increased in the 21st century. Major underlying causes for these diseases are inflammation and oxidative stress. Accordingly, natural products and their bioactive components are obvious therapeutic agents for these diseases, given their antioxidant and anti-inflammatory properties. Research in this area has been significantly expanded to include chemical identification of these compounds using advanced analytical techniques, determining their mechanism of action, food fortification and supplement development, and enhancing their bioavailability and bioactivity using nanotechnology. These timely topics were discussed at the 20th Frontier Scientists Workshop sponsored by the Korean Academy of Science and Technology, held at the University of Hawaii at Manoa on 23 November 2019. Scientists from South Korea and the U.S. shared their recent research under the overarching theme of Bioactive Compounds, Nanoparticles, and Disease Prevention. This review summarizes presentations at the workshop to provide current knowledge of the role of natural products in the prevention and treatment of metabolic diseases.

show abstract

“…α-Cadinol, sesquiterpenoid separated from T. cryptomerioides heartwood, exhibited antiproliferative activity on Human colon adenocarcinoma cells [3]. Taiwanin A, the dibenzyl-γ-butyrolactone-type lignan, displayed superior antitumor activity against A-549 lung carcinoma and MCF-7 breast adenocarcinoma and colon adenocarcinoma cell line among the isolated lignans and sesquiterpenoids from T. cryptomerioides heartwood extract [1,9].…”

Section: Introductionmentioning

confidence: 99%

Cytotoxicity and Apoptosis Induction of 6,7-Dehydroroyleanone from Taiwania cryptomerioides Bark Essential Oil in Hepatocellular Carcinoma Cells

Chen

Chang

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

The objective of the present study is to evaluate the cytotoxicity of Taiwania cryptomerioides essential oil and its phytochemical on the Hep G2 cell line (human hepatocellular carcinoma). Bark essential oil has significant cytotoxicity to Hep G2 cells, and S3 fraction is the most active fraction in cytotoxicity to Hep G2 cells among the six fractions. The diterpenoid quinone, 6,7-dehydroroyleanone, was isolated from the active S3 fraction by bioassay-guided isolation. 6,7-Dehydroroyleanone exhibited significant cytotoxicity in Hep G2 cells, and the efficacy of 6,7-dehydroroyleanone was better than the positive control, etoposide. Apoptosis analysis of Hep G2 cells with different treatments was characterized via flow cytometry to confirm the cell death situation. Etoposide and 6,7-dehydroroyleanone could induce the apoptosis in Hep G2 cells using flow cytometric assay. Results revealed 6,7-dehydroroyleanone from T. cryptomerioides bark essential oil can be a potential phytochemical to develop the anticancer chemotherapeutic agent for the treatment of the human hepatocellular carcinoma.

show abstract

Taiwanin A targets non-steroidal anti-inflammatory drug-activated gene-1 in human lung carcinoma

Cited by 9 publications

References 23 publications

Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases

Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases

Natural Products in the Prevention of Metabolic Diseases: Lessons Learned from the 20th KAST Frontier Scientists Workshop

Cytotoxicity and Apoptosis Induction of 6,7-Dehydroroyleanone from Taiwania cryptomerioides Bark Essential Oil in Hepatocellular Carcinoma Cells

Contact Info

Product

Resources

About